By John Broton From EMQ News & Analysis

BeiGene, Ltd. (BGNE) plans to raise $126 million in an IPO on Thursday, February 4th. The company will be issuing 5,500,000 shares at a price of $22.00-$24.00 per share.

In the last 12 months, BeiGene, Ltd. generated $5.5 million in revenue and had a net loss of $33.6 million. BeiGene, Ltd. has a market cap of $685.9 million.

Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

BeiGene, Ltd. provided the following description of their company for its IPO: “We are a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival. We further believe that discovery of next-generation cancer therapies requires new research tools. To that end, we have developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support our drug discovery effort. “.

BeiGene, Ltd. was founded in 2010 and has 194 employees. The company is located at c/o Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands and can be reached via phone at +1 (345) 949 4123 or on the web at http://www.beigene.com.